



STATE MEDICAID P&T COMMITTEE MEETING
THURSDAY, February 18, 2010
7:00 a.m. to 8:30 a.m.
Cannon Health Building
Room 114



MINUTES

Committee Members Present:

Ellie Brownstein, M.D.

Kort Delost, R.Ph.

Karen Gunning, PharmD.

Duane Parke, R.Ph.

Beth Johnson, R.Ph.

Michael Flynn, M.D.

Brandon Jennings, PharmD.

Raymond Ward, M.D.

Board Members Excused:

Dept. of Health/Div. of Health Care Financing Staff Present:

Jennifer Zeleny, CPhT, MPH

Lisa Hulbert, R.Ph.

Richard Sorenson, R.N.

Tim Morley, R.Ph.

University of Utah Drug Information Center Staff Present:

Chris Beckwith, PharmD.

Dave Peterson, PharmD.

Other Individuals Present:

Guli Tefferi, Eisai

Brooks Hubbard, BIPI

Emily Goldman, U of U

Alan Bailey, Pfizer

Shelley Blam, Eisai

Marlene Mendola, BIPI

Sean Leavitt, U of U

Meeting conducted by: Dr. Raymond Ward, Co-Chairperson.

-
1. Minutes for January 2010 were reviewed, corrected, and approved. Brandon Jennings moved to approve the minutes. Dr. Flynn seconded the motion. The motion passed with unanimous votes by Brandon Jennings, Dr. Flynn, Karen Gunning, Dr. Ward, and Duane Parke.
 2. DUR Board Update: Lisa Hulbert addressed the Committee. At the last meeting on February 11, the DUR Board considered new anti-gout agents and addressed the over-use of Synera. The DUR Board is also working on new criteria for non-preferred PPIs. Next month the DUR Board will consider Zovirax ointment, hydroxyprogesterone caproate, and age limits on sedative hypnotics.
 3. Housekeeping: Duane Parke addressed the Committee. Next month's meeting will be on oral NSAIDS only. No decision has been made on Low Molecular Weight Heparins yet. Contracts should be going to manufacturers this week. Dr. Jerome Wohleb resigned from the P&T Committee. Beth

Johnson, R.Ph., was seated in his place.

4. Inhaled Anticholinergic Agnets: Dr. Dave Peterson of the University of Utah Drug Information Service addressed the Committee and presented a report on single-drug anticholinergic multi-dose inhalers prepared by the DIS.

Dr. Flynn asked whether compliance was assessed in the studies analyzed in the DIS report. Dr. Peterson stated that it was not. Intention to treat was used in the trials. Technique assessments were not done in the trials.

Karen Gunning asked if tiotropium is available in nebulizer or combination products. Dr. Peterson stated that it is not.

Dr. Marlene Mandiola from Boehringer Ingelheim addressed the Committee in favor of Spiriva inhalers.

Karen Gunning asked Dr. Mandiola about the discontinuation rate in the Uplift study cited in her comments. The discontinuation rate in the placebo arm was 45% and in the tiotropium arm 35%. Karen asked if there was a measure of adherence. That was recorded during the treatment.

Karen Gunning asked if there could be a role of combined use. Dr. Peterson stated that there was not a lot of data to support it, but the best bet for combined use would be a different class (i.e. short-acting albuterol with long-acting tiotropium). Karen asked if there is a current edit in the system to prevent concomitant use of tiotropium and ipratropium. There is not.

Dr. Ward stated that he felt based on the presentation that the agents are similar, but that tiotropium was more effective in several small ways. The Committee agreed, but Dr. Brownstein added that there is an occasional rare child that needs ipratropium.

Karen Gunning stated that she has also had experiences with COPD patients who benefit psychologically from having something like ipratropium to use more often.

Kort DeLost moved that only tiotropium be included on the PDL. There was no second.

Dr. Flynn moved that both agents be included on the PDL. Brandon Jennings seconded the motions. The motion passed with votes by Karen Gunning, Dr. Ward, Duane Parke, Brandon Jennings, Dr. Flynn, Dr. Brownstein, and Beth Johnson. Kort DeLost abstained.

5. Newer Antiemetics: Dr. Christina Beckwith addressed the Committee and presented the Oregon Health Sciences University Review on the class. The University of Utah prepared supplemental information on granisetron transdermal and fosaprepitant injection that was also presented.

Dr. Shelley Blam of Eisai addressed the P&T Committee in favor of Aloxi for the treatment of Chemotherapy Induced Nausea and Vomiting (CINV).

Karen Gunning asked if it is primarily given in a clinic setting. Dr. Blam stated that it is commonly given in infusion centers, and is not likely to be used at home. Duane Parke stated the Medicaid does collect primary rebates for infusion products billed by J-code.

The Committee asked Rick Sorenson whether the products require prior authorization. They are, and the primary uses are split between pregnancy, chemotherapy induced nausea. Ondansetron sees the most use of all of the agents.

Dr. Beckwith stated that ondansetron is the only agent that has been studied for hyper emesis in pregnancy.

To illustrate the cost disparity in this drug class, Dr. Ward related an experience where he received a prescription for his son for dolasetron that was going to cost \$2,100 and found out he would only have to pay \$25 for ondansetron. He asked the physician who wrote the prescription if there was a particular need for dolasetron, and found out that the doctor only prescribed that particular agent because it was in the chart.

Dr. Flynn and Dr. Brownstein felt that ondansetron had available safety and efficacy studies in pediatrics and should be included for that reason. Dr. Beckwith also suggested that the committee may want to consider palonosetron separately due to the fact that it has only been studied for chemotherapy-induced nausea and vomiting, because it is very long acting, and because it is only available in injectable forms. The other drugs are pretty well interchangeable, but palonosetron is not.

The Committee felt that neurochynin inhibitors should not be considered with the 5HT₃'s for the PDL.

Dr. Flynn moved that overall, the agents are equivalent in safety and efficacy, palonosetron should not be alone on the PDL, and ondansetron should be included due to evidence in pediatrics. Dr. Brownstein seconded the motion. The motion passed with unanimous votes by Karen Gunning, Dr. Ward, Duane Parke, Brandon Jennings, Dr. Flynn, Dr. Brownstein, Kort Delost, and Beth Johnson.

Next Meeting Set for Thursday, March 18, 2010
Meeting Adjourned.

Minutes prepared by Jennifer Zeleny